002370 亚太药业
已收盘 03-06 15:00:00
资讯
新帖
简况
亚太药业（002370）披露对外投资设立子公司公告，3月4日股价上涨0.31%
证券之星 · 03-04 22:26
亚太药业（002370）披露对外投资设立子公司公告，3月4日股价上涨0.31%
亚太药业(002370.SZ)子公司拟参设亚钛星浩 完善业务链条
智通财经 · 03-04 17:29
亚太药业(002370.SZ)子公司拟参设亚钛星浩 完善业务链条
亚太药业在浙江成立控股新公司
财闻 · 03-03
亚太药业在浙江成立控股新公司
亚太药业（002370）披露全资子公司完成工商登记公告，3月2日股价下跌3.78%
证券之星 · 03-02
亚太药业（002370）披露全资子公司完成工商登记公告，3月2日股价下跌3.78%
亚太药业：公司预计2025年度营业收入3.5亿元-3.7亿元
证券之星 · 02-05
亚太药业：公司预计2025年度营业收入3.5亿元-3.7亿元
股市必读：亚太药业（002370）预计2025年全年营业收入3.5亿元至3.7亿元
证券之星 · 02-02
股市必读：亚太药业（002370）预计2025年全年营业收入3.5亿元至3.7亿元
亚太药业（002370）披露2025年度业绩预告，1月30日股价上涨0.28%
证券之星 · 01-30
亚太药业（002370）披露2025年度业绩预告，1月30日股价上涨0.28%
股市必读：亚太药业（002370）1月27日收盘跌5.22%，主力净流出1388.9万元
证券之星 · 01-28
股市必读：亚太药业（002370）1月27日收盘跌5.22%，主力净流出1388.9万元
亚太药业（002370）披露召开2026年第一次临时股东大会通知，1月23日股价上涨0.67%
证券之星 · 01-23
亚太药业（002370）披露召开2026年第一次临时股东大会通知，1月23日股价上涨0.67%
亚太药业：股份转让获深交所合规确认
证券之星 · 2025-12-18
亚太药业：股份转让获深交所合规确认
亚太药业（002370）披露拟变更会计师事务所及多项制度修订公告，12月8日股价上涨2.31%
证券之星 · 2025-12-08
亚太药业（002370）披露拟变更会计师事务所及多项制度修订公告，12月8日股价上涨2.31%
亚太药业：优化产品结构拓展海外市场
证券之星 · 2025-12-05
亚太药业：优化产品结构拓展海外市场
股市必读：亚太药业（002370）11月18日收盘跌6.19%，主力净流出2501.85万元
证券之星 · 2025-11-19
股市必读：亚太药业（002370）11月18日收盘跌6.19%，主力净流出2501.85万元
一款仿制药未过评，新东家能拯救亚太药业吗？
视频滚动新闻 · 2025-11-14
一款仿制药未过评，新东家能拯救亚太药业吗？
亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准
智通财经 · 2025-11-06
亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准
11月4日亚太药业（002370）龙虎榜数据：机构净买入8831.23万元
证券之星 · 2025-11-04
11月4日亚太药业（002370）龙虎榜数据：机构净买入8831.23万元
异动快报：亚太药业（002370）10月31日11点2分触及涨停板
证券之星 · 2025-10-31
异动快报：亚太药业（002370）10月31日11点2分触及涨停板
亚太药业（002370）2025年三季报简析：净利润同比增长2909.49%，三费占比上升明显
证券之星 · 2025-10-30
亚太药业（002370）2025年三季报简析：净利润同比增长2909.49%，三费占比上升明显
亚太药业(002370)9月30日股东户数9.15万户，较上期增加66%
证券之星 · 2025-10-28
亚太药业(002370)9月30日股东户数9.15万户，较上期增加66%
股市必读：亚太药业（002370）登10月17日交易所龙虎榜
证券之星 · 2025-10-20
股市必读：亚太药业（002370）登10月17日交易所龙虎榜
公司概况
公司名称：
浙江亚太药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-03-16
主营业务：
浙江亚太药业股份有限公司的主营业务是化学制剂的研发、生产和销售。公司的主要产品是抗生素类药品和非抗生素类药品。
发行价格：
16.00
{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":6.75,"timestamp":1772780634000,"preClose":6.63,"halted":0,"volume":16272250,"delay":0,"changeRate":0.0181,"floatShares":746000000,"shares":746000000,"eps":0.181,"marketStatus":"已收盘","change":0.12,"latestTime":"03-06 15:00:00","open":6.62,"high":6.76,"low":6.58,"amount":109000000,"amplitude":0.0271,"askPrice":6.76,"askSize":5248,"bidPrice":6.75,"bidSize":1063,"shortable":0,"etf":0,"ttmEps":0.181,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773019800000},"marketStatusCode":5,"adr":0,"adjPreClose":6.63,"symbolType":"stock","openAndCloseTimeList":[[1772760600000,1772767800000],[1772773200000,1772780400000]],"highLimit":7.29,"lowLimit":5.97,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":745667530,"isCdr":false,"pbRate":4.41,"roa":"--","peRate":37.292818,"roe":"9.21%","epsLYR":0.05,"committee":-0.249903,"marketValue":5033000000,"turnoverRate":0.0218,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-03-09。","floatMarketCap":5033000000},"requestUrl":"/m/hq/s/002370/wiki","defaultTab":"wiki","newsList":[{"id":"2616556209","title":"亚太药业（002370）披露对外投资设立子公司公告，3月4日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616556209","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616556209?lang=zh_cn&edition=full","pubTime":"2026-03-04 22:26","pubTimestamp":1772634379,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘，亚太药业报收于6.49元，较前一交易日上涨0.31%，最新总市值为48.39亿元。该股当日开盘6.45元，最高6.57元，最低6.39元，成交额达8861.47万元，换手率为1.83%。近日，亚太药业披露《关于对外投资设立子公司的公告》。公告显示，公司全资子公司浙江雅泰利众控股有限公司与海南泰泽丰医药科技有限公司于2026年3月4日签订《投资合作协议》，拟共同出资设立浙江亚钛星浩药业有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400040285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2616535336","title":"亚太药业(002370.SZ)子公司拟参设亚钛星浩 完善业务链条","url":"https://stock-news.laohu8.com/highlight/detail?id=2616535336","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616535336?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:29","pubTimestamp":1772616565,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)公告，公司全资子公司雅泰利众于2026年3月4日与泰泽丰医药签订《投资合作协议》，双方拟共同出资设立浙江亚钛星浩药业有限公司(暂定名，简称“亚钛星浩”)，亚钛星浩注册资本1000万元，其中雅泰利众出资600万元，占注册资本的60%，泰泽丰医药出资400万元，占注册资本的40%。据悉，实施该事项有利于进一步完善公司在医药领域的业务链条，提升产业协同效应与综合竞争实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2616239070","title":"亚太药业在浙江成立控股新公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2616239070","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616239070?lang=zh_cn&edition=full","pubTime":"2026-03-03 13:25","pubTimestamp":1772515500,"startTime":"0","endTime":"0","summary":"企查查APP显示，近日，浙江雅泰利众控股有限公司成立，注册资本5000万元，经营范围包含：控股公司服务；以自有资金从事投资活动；自有资金投资的资产管理服务等。企查查股权穿透显示，该公 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260303/c675039714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2616355817","title":"亚太药业（002370）披露全资子公司完成工商登记公告，3月2日股价下跌3.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355817","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616355817?lang=zh_cn&edition=full","pubTime":"2026-03-02 22:30","pubTimestamp":1772461842,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘，亚太药业报收于6.62元，较前一交易日下跌3.78%，最新总市值为49.36亿元。近日，浙江亚太药业股份有限公司发布公告称，公司拟以自有资金5,000.00万元设立全资子公司浙江雅泰利众投资控股有限公司。该子公司已完成工商登记手续，并取得绍兴市越城区市场监督管理局颁发的营业执照。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200039864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2609701003","title":"亚太药业：公司预计2025年度营业收入3.5亿元-3.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609701003","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609701003?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:51","pubTimestamp":1770295895,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业02月04日在投资者关系平台上答复投资者关心的问题。根据《深圳证券交易所股票上市规则》相关规定，最近一个会计年度经审计的利润总额、净利润、扣除非经常性损益后的净利润三者孰低为负值，且扣除后的营业收入低于3亿元，深交所对其股票交易实施退市风险警示。根据公司于2026年1月31日披露的《2025年度业绩预告》，公司预计2025年度营业收入3.5亿元-3.7亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2608889594","title":"股市必读：亚太药业（002370）预计2025年全年营业收入3.5亿元至3.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889594","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889594?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:15","pubTimestamp":1769973313,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，亚太药业报收于7.11元，上涨0.28%，换手率2.13%，成交量15.89万手，成交额1.13亿元。亚太药业发布业绩预告，预计2025年全年营业收入3.5亿元至3.7亿元。公司公告汇总2025年度业绩预告浙江亚太药业股份有限公司预计2025年度归属于上市公司股东的净利润为10,000万元至12,000万元，同比增长192.06%至250.47%。公司已于2025年12月26日支付部分款项98.53万元，2026年1月9日支付剩余款项517.59万元，并申请解除冻结。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2607904496","title":"亚太药业（002370）披露2025年度业绩预告，1月30日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607904496","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607904496?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:57","pubTimestamp":1769785031,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，亚太药业报收于7.11元，较前一交易日上涨0.28%，最新总市值为53.02亿元。该股当日开盘7.08元，最高7.19元，最低7.03元，成交额达1.13亿元，换手率为2.13%。近日，浙江亚太药业股份有限公司披露《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润为10,000万元至12,000万元，同比增长192.06%至250.47%；扣除非经常性损益后的净利润为亏损4,200万元至6,000万元，同比下降49.30%至113.28%；营业收入预计为35,000万元至37,000万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2606317157","title":"股市必读：亚太药业（002370）1月27日收盘跌5.22%，主力净流出1388.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606317157","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606317157?lang=zh_cn&edition=full","pubTime":"2026-01-28 01:45","pubTimestamp":1769535914,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，亚太药业报收于7.45元，下跌5.22%，换手率9.43%，成交量70.33万手，成交额5.22亿元。当日关注点来自交易信息汇总：1月27日亚太药业收盘报7.45元，跌5.22%，主力资金当日净流出1388.9万元。前10个交易日资金流向情况：主力资金累计净流出3608.04万元，股价累计下跌1.28%；融资余额累计减少2737.42万元，融券余量累计增加0股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800001079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2605406836","title":"亚太药业（002370）披露召开2026年第一次临时股东大会通知，1月23日股价上涨0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605406836","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605406836?lang=zh_cn&edition=full","pubTime":"2026-01-23 22:29","pubTimestamp":1769178556,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，亚太药业报收于7.5元，较前一交易日上涨0.67%，最新总市值为55.93亿元。近日，浙江亚太药业股份有限公司发布《关于召开2026年第一次临时股东会的通知》。会议审议事项包括选举第八届董事会5名非独立董事和3名独立董事，以及修订《公司章程》的议案。《公司章程》修订属于特别决议事项，须经出席股东会的股东所持有效表决权的2/3以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2592261269","title":"亚太药业：股份转让获深交所合规确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2592261269","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592261269?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:36","pubTimestamp":1766028972,"startTime":"0","endTime":"0","summary":"2025年12月8日，公司收到深圳证券交易所下发的《深圳证券交易所上市公司股份协议转让确认书》，深圳证券交易所已完成对本次股份协议转让相关材料的合规确认，确认书有效期为六个月，转让双方需按照确认书载明的转受让股份数量一次性办理过户登记。本次股份转让事项尚需在中国证券登记结算公司深圳分公司办理股份过户登记手续。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800012785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","002370"],"gpt_icon":0},{"id":"2589305359","title":"亚太药业（002370）披露拟变更会计师事务所及多项制度修订公告，12月8日股价上涨2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589305359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589305359?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:19","pubTimestamp":1765203578,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，亚太药业报收于7.53元，较前一交易日上涨2.31%，最新总市值为56.15亿元。该股当日开盘7.4元，最高7.67元，最低7.4元，成交额达4.03亿元，换手率为7.19%。近日，浙江亚太药业股份有限公司发布公告称，公司将于2025年12月24日召开2025年第三次临时股东大会，会议由董事会召集，现场会议时间为当日14:00，网络投票时间为9:15至15:00。股权登记日为2025年12月18日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800034891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2589851238","title":"亚太药业：优化产品结构拓展海外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2589851238","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589851238?lang=zh_cn&edition=full","pubTime":"2025-12-05 09:24","pubTimestamp":1764897856,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业12月04日在投资者关系平台上答复投资者关心的问题。公司目前正积极应对市场环境变化，通过优化产品结构，拓展营销渠道，探索新营销模式和海外市场的开发，加大费用管控，降本增效，努力提升盈利能力，以期实现公司的持续、稳定、健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500005733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2584895952","title":"股市必读：亚太药业（002370）11月18日收盘跌6.19%，主力净流出2501.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584895952","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584895952?lang=zh_cn&edition=full","pubTime":"2025-11-19 01:00","pubTimestamp":1763485254,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，亚太药业报收于8.34元，下跌6.19%，换手率15.01%，成交量111.91万手，成交额9.44亿元。交易信息汇总股价提醒11月18日亚太药业收盘报8.34元，跌6.19%，当日成交1.12亿元。前10个交易日资金流向情况：主力资金累计净流出3.82亿元，股价累计下跌7.86%；融资余额累计增加1.15亿元，融券余量累计增加0股。资金流向11月18日主力资金净流出5240.31万元；游资资金净流入543.98万元；散户资金净流入4696.33万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900000623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2583526335","title":"一款仿制药未过评，新东家能拯救亚太药业吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583526335","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583526335?lang=zh_cn&edition=full","pubTime":"2025-11-14 13:06","pubTimestamp":1763096760,"startTime":"0","endTime":"0","summary":"亚太药业盐酸地尔硫䓬片一致性评价申请被国家药监局不予批准，虽称未过评不影响当期业绩，但隐忧不小。公司已连续六年扣非亏损超25亿元，2024年营收逼近退市警戒线，2025年前三季度扣非仍亏损。公司拟变更控股股东并定增7亿用于新药研发，但创新项目短期难有实质贡献，仍需稳住仿制药基本盘。近年来仿制药监管加码，BE试验成研发“拦路虎”，行业洗牌加速，集中度将进一步提升。(AI生成)\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-11-14/doc-infxiwew9294372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2581560210","title":"亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2581560210","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581560210?lang=zh_cn&edition=full","pubTime":"2025-11-06 15:55","pubTimestamp":1762415705,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)公告，公司近日收到国家药品监督管理局下发的关于盐酸地尔硫䓬片一致性评价的申请不予批准的通知书。盐酸地尔硫䓬片适用于心绞痛和轻、中度高血压的治疗。据通知书内容，本次不予批准的原因是：本次申报BE研究不能支持生物等效性结论。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亚太药业(002370.SZ)：盐酸地尔硫䓬片一致性评价申请不予批准","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2580861387","title":"11月4日亚太药业（002370）龙虎榜数据：机构净买入8831.23万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580861387","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580861387?lang=zh_cn&edition=full","pubTime":"2025-11-04 17:32","pubTimestamp":1762248774,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2025年11月4日公布的交易公开信息显示，亚太药业因日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2025年11月4日收盘，亚太药业报收于9.06元，上涨3.9%，换手率38.87%，成交量289.81万手，成交额25.92亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入8831.23万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400027816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2579484794","title":"异动快报：亚太药业（002370）10月31日11点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2579484794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579484794?lang=zh_cn&edition=full","pubTime":"2025-10-31 11:05","pubTimestamp":1761879925,"startTime":"0","endTime":"0","summary":"证券之星10月31日盘中消息，11点2分亚太药业触及涨停板。目前价格7.93，上涨9.99%。其所属行业化学制药目前上涨。领涨股为舒泰神。该股为幽门螺杆菌概念，医药，化学原料药概念热股，当日幽门螺杆菌概念概念上涨2.82%，医药概念上涨2.52%，化学原料药概念上涨2.47%。10月30日的资金流向数据方面，主力资金净流入1118.15万元，占总成交额1.41%，游资资金净流出872.06万元，占总成交额1.1%，散户资金净流出246.1万元，占总成交额0.31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100019876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2579130261","title":"亚太药业（002370）2025年三季报简析：净利润同比增长2909.49%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2579130261","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579130261?lang=zh_cn&edition=full","pubTime":"2025-10-30 06:27","pubTimestamp":1761776830,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚太药业发布2025年三季报。截至本报告期末，公司营业总收入2.28亿元，同比下降25.59%，归母净利润9719.5万元，同比上升2909.49%。按单季度数据看，第三季度营业总收入7623.1万元，同比下降10.21%，第三季度归母净利润-798.15万元，同比上升10.67%。本报告期亚太药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达43.89%。去年的净利率为8.45%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000005603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2578398479","title":"亚太药业(002370)9月30日股东户数9.15万户，较上期增加66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578398479","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578398479?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:32","pubTimestamp":1761643977,"startTime":"0","endTime":"0","summary":"证券之星消息，近日亚太药业披露，截至2025年9月30日公司股东户数为9.15万户，较6月30日增加3.64万户，增幅为66.0%。在化学制药行业个股中，亚太药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.38万户。从股价来看，2025年6月30日至2025年9月30日，亚太药业区间涨幅为49.21%，在此期间股东户数增加3.64万户，增幅为66.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800031760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2576077731","title":"股市必读：亚太药业（002370）登10月17日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2576077731","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576077731?lang=zh_cn&edition=full","pubTime":"2025-10-20 01:34","pubTimestamp":1760895249,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，亚太药业报收于7.75元，上涨2.65%，换手率37.93%，成交量282.83万手，成交额21.96亿元。当日关注点来自交易信息汇总：10月17日主力资金净流入3792.3万元，游资资金净流出4575.54万元。来自龙虎榜上榜：亚太药业因日振幅值达15%及日换手率达20%于10月17日登龙虎榜，近5个交易日内第2次上榜。龙虎榜上榜沪深交易所2025年10月17日公布的交易公开信息显示，亚太药业因日振幅值达到15%的前5只证券，日换手率达到20%的前5只证券登上龙虎榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000000577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772823003966,"stockEarnings":[{"period":"1week","weight":-0.0189},{"period":"1month","weight":-0.0506},{"period":"3month","weight":-0.0829},{"period":"6month","weight":0.0465},{"period":"1year","weight":1.0089},{"period":"ytd","weight":-0.0766}],"compareEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":0.0054},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"91465人(较上一季度增加66.00%)","perCapita":"8152股","listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","registeredCapital":"74566万元","survey":" 浙江亚太药业股份有限公司的主营业务是化学制剂的研发、生产和销售。公司的主要产品是抗生素类药品和非抗生素类药品。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}